Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
Federal Reserve Vice Chair Richard Clarida said Friday the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
The death comes as federal and state health officials investigate a slew of lung illnesses in connection to e-cigarette use.Health and Scienceread more
Supreme Court Justice Ruth Bader Ginsburg has completed a three-week course of radiation therapy for cancer, the top court said in a statement Friday.Politicsread more
Multinationals that rely on the supply chain from China are tumbling after President Donald Trump ordered them to find alternatives to their Chinese operations.Marketsread more
Lowe's is vying for a category of customer that Home Depot has traditionally dominated — the professional contractor.Retailread more
Epstein, a former friend of Presidents Donald Trump and Bill Clinton, was arrested by FBI agents in New Jersey in early July as he stepped off his private plane, which had...Politicsread more
Billionaire investor Carl Ichan recently gave vocal warnings that the "joy ride is over for stocks." But other experts say the reality going into the fourth quarter of 2015 is more nuanced.
While policymakers such as the Federal Reserve and Congress have hammered the financial and biotechnology sectors, the market outlook into 2016 relies on modestly higher earnings, Richard Madigan, chief investment officer for J.P. Morgan Private Bank, told CNBC's "Power Lunch."
"We have not given up on health care," said Madigan, who told CNBC the rough quarter for health care was "politically motivated and headline driven, not earnings driven or M&A driven. With structural stuff we see going on with quality pharma, with strong pipelines and strong with dividend pays, we still feel good about that [sector]."
The biotech sector has been steeped in controversy surrounding large price hikes for pharmaceuticals. iShares Nasdaq Biotechnology ETF rebounded almost 5 percent Wednesday after falling more than 20 percent off 52-week highs earlier in the week.
But Susan Fulton, FBB Capital Partners president, told CNBC that there are still companies in the health-care field that are not attached to the global slowdown.
"We are not into biotechs right now. ... We are very much into drug distributors," Fulton said. "Companies like McKesson, who are part of the supply chain, they don't have any of the ethical or competitive issues that are causing that sector to have problems. We like the sector, we don't like the problems. "
Robert Pavlik, Boston Private Wealth chief market strategist, agreed that health care, technology and consumer discretionary stocks would continue to benefit from earnings' "falling in to place." But he's also watching for a promising employment report and an October interest rate hike from the Federal Reserve to boost financial sector stocks.
Madigan, on the other hand, said he recently cut financials. The iShares U.S. Financial Services ETF closed up 1.35 percent Wednesday, but was still down almost 7 percent year-to-date.
"That's really a function of the Fed letting us down ... letting me down in September," Madigan said. "Markets were primed to rally, the Fed made people question growth, and that's smart from an optionality perspective for them, but we're going to have to work through that."
Though stocks closed around 1.5 percent higher Wednesday, they still posted the worst quarter in four years.
"Today is a pretty key day," Pavlik said. "You need to watch the market and see where it closes."
—CNBC's Evelyn Cheng contributed to this report.